Haverford Trust Co Acquires 34,560 Shares of Eli Lilly and Company (NYSE:LLY)

Haverford Trust Co lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 983.2% during the 4th quarter, Holdings Channel reports. The firm owned 38,075 shares of the company’s stock after purchasing an additional 34,560 shares during the quarter. Haverford Trust Co’s holdings in Eli Lilly and Company were worth $29,394,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Interchange Capital Partners LLC grew its position in shares of Eli Lilly and Company by 11.3% during the 4th quarter. Interchange Capital Partners LLC now owns 1,181 shares of the company’s stock worth $912,000 after buying an additional 120 shares during the period. ICW Investment Advisors LLC boosted its stake in Eli Lilly and Company by 1,157.6% during the fourth quarter. ICW Investment Advisors LLC now owns 6,615 shares of the company’s stock worth $5,107,000 after acquiring an additional 6,089 shares in the last quarter. Jackson Thornton Wealth Management LLC grew its holdings in Eli Lilly and Company by 37.6% in the fourth quarter. Jackson Thornton Wealth Management LLC now owns 779 shares of the company’s stock worth $601,000 after purchasing an additional 213 shares during the period. Woodmont Investment Counsel LLC grew its holdings in Eli Lilly and Company by 121.2% in the fourth quarter. Woodmont Investment Counsel LLC now owns 10,687 shares of the company’s stock worth $8,251,000 after purchasing an additional 5,856 shares during the period. Finally, Congress Wealth Management LLC DE raised its holdings in shares of Eli Lilly and Company by 1.9% during the fourth quarter. Congress Wealth Management LLC DE now owns 48,606 shares of the company’s stock valued at $37,525,000 after purchasing an additional 897 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.13% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts have recently commented on LLY shares. Leerink Partners set a $950.00 target price on Eli Lilly and Company in a research note on Friday, January 17th. Citigroup dropped their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Truist Financial raised their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Finally, Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Three analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,009.72.

Eli Lilly and Company Stock Down 0.4 %

Shares of NYSE LLY opened at $839.44 on Monday. The firm has a fifty day simple moving average of $835.99 and a two-hundred day simple moving average of $838.30. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The firm has a market capitalization of $795.93 billion, a PE ratio of 71.69, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company announced that its Board of Directors has authorized a stock buyback plan on Monday, December 9th that permits the company to buyback $15.00 billion in shares. This buyback authorization permits the company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s leadership believes its shares are undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.